Also known as Iressa
Gefitinib (INN, pron.: /ɡɛˈfɪtɨnɪb/, trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.Source: Wikipedia
Estimated Total Cost: $1449.8 for an average of 28 days supply
Patients are most commonly prescribed gefitinib to treat blastomycosis, rabies, west nile virus, and pick disease.